These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36156003)

  • 61. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Biomarkers for Immunotherapy: Current Developments and Challenges.
    Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genomic Instability and Clonal Evolution in Chronic Lymphocytic Leukemia: Clinical Relevance.
    Condoluci A; Rossi D
    J Natl Compr Canc Netw; 2020 Dec; 19(2):227-233. PubMed ID: 33383567
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus.
    Wan PK; Ryan AJ; Seymour LW
    Mol Ther; 2021 May; 29(5):1668-1682. PubMed ID: 33845199
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.
    Pi YN; Qi WC; Xia BR; Lou G; Jin WL
    Front Immunol; 2021; 12():697083. PubMed ID: 34295338
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Engineering Multidimensional Evolutionary Forces to Combat Cancer.
    McCoach CE; Bivona TG
    Cancer Discov; 2019 May; 9(5):587-604. PubMed ID: 30992280
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Computational Approaches for the Investigation of Intra-tumor Heterogeneity and Clonal Evolution from Bulk Sequencing Data in Precision Oncology Applications.
    Laganà A
    Adv Exp Med Biol; 2022; 1361():101-118. PubMed ID: 35230685
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunosuppressive Roles of Galectin-1 in the Tumor Microenvironment.
    Huang Y; Wang HC; Zhao J; Wu MH; Shih TC
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680031
    [TBL] [Abstract][Full Text] [Related]  

  • 70. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
    Huang L; Xu H; Peng G
    Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adapting clinical paradigms to the challenges of cancer clonal evolution.
    Murugaesu N; Chew SK; Swanton C
    Am J Pathol; 2013 Jun; 182(6):1962-71. PubMed ID: 23708210
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
    Riaz N; Havel JJ; Makarov V; Desrichard A; Urba WJ; Sims JS; Hodi FS; Martín-Algarra S; Mandal R; Sharfman WH; Bhatia S; Hwu WJ; Gajewski TF; Slingluff CL; Chowell D; Kendall SM; Chang H; Shah R; Kuo F; Morris LGT; Sidhom JW; Schneck JP; Horak CE; Weinhold N; Chan TA
    Cell; 2017 Nov; 171(4):934-949.e16. PubMed ID: 29033130
    [TBL] [Abstract][Full Text] [Related]  

  • 73. High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes.
    Singh M; Al-Eryani G; Carswell S; Ferguson JM; Blackburn J; Barton K; Roden D; Luciani F; Giang Phan T; Junankar S; Jackson K; Goodnow CC; Smith MA; Swarbrick A
    Nat Commun; 2019 Jul; 10(1):3120. PubMed ID: 31311926
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment.
    Jiang Z; Liu Z; Li M; Chen C; Wang X
    EBioMedicine; 2019 Apr; 42():431-442. PubMed ID: 30935888
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Top 10 Challenges in Cancer Immunotherapy.
    Hegde PS; Chen DS
    Immunity; 2020 Jan; 52(1):17-35. PubMed ID: 31940268
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Toward integrative cancer immunotherapy: targeting the tumor microenvironment.
    Emens LA; Silverstein SC; Khleif S; Marincola FM; Galon J
    J Transl Med; 2012 Apr; 10():70. PubMed ID: 22490302
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Natural killer cells in cancer biology and therapy.
    Wu SY; Fu T; Jiang YZ; Shao ZM
    Mol Cancer; 2020 Aug; 19(1):120. PubMed ID: 32762681
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunologic Gene Sets Reveal Features of the Tumor Immune Microenvironment and Predict Prognosis and Immunotherapy Response: A Pan-Cancer Analysis.
    Pan H; Pan J; Li P; Wu J
    Front Immunol; 2022; 13():858246. PubMed ID: 35493519
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
    Rivadeneira DB; Delgoffe GM
    Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome.
    Chang WH; Lai AG
    Cancer Lett; 2020 Sep; 487():34-44. PubMed ID: 32470490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.